Back to top

Image: Shutterstock

Fiserv (FISV) to Report Q3 Earnings: What's in The Offing?

Read MoreHide Full Article

Fiserv, Inc. (FISV - Free Report) is scheduled to report third-quarter 2020 results on Oct 27, after the bell.

The company’s earnings missed the Zacks Consensus Estimate in the second quarter of 2020. The company delivered an earnings surprise of a negative 0.7% in the last four quarters, on average.

Expectations This Time Around

The Zacks Consensus Estimate for adjusted revenues is pegged at $3.56 billion, indicating growth of 13.8% from the year-ago quarter’s reported figure. The expected growth is likely to be driven by incremental revenues from the First Data acquisition which should aid the Acceptance, Payments and Corporate and Other segments.

Revenue growth and benefits of cost synergies are likely to have boosted Fiserv’s second-quarter 2020 earnings, the Zacks Consensus Estimate for which is pegged at $1.16 per share, indicating year-over-year growth of 13.7%.

What Our Model Says

Our proven model predicts an earnings beat for Fiserv this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Fiserv has an Earnings ESP of +3.86% and a Zacks Rank #3.

Fiserv, Inc. Price and EPS Surprise

Fiserv, Inc. Price and EPS Surprise

Fiserv, Inc. price-eps-surprise | Fiserv, Inc. Quote

Other Stocks That Warrant a Look

Aptiv (APTV - Free Report) has an Earnings ESP of +15.51% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Booz Allen Hamilton (BAH - Free Report) has an Earnings ESP of +3.64% and a Zacks Rank #3.

Waste Connections (WCN - Free Report) has an Earnings ESP of +0.32% and a Zacks Rank #3.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases.

They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>